Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1996 1
1997 2
1998 1
2000 1
2002 1
2003 1
2008 4
2009 1
2010 3
2011 3
2012 5
2013 6
2014 2
2016 2
2017 3
2018 2
2019 2
2020 2
2021 2
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma"
Page 1
Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma.
Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, Shariat SF, Saad F, Chun FKH, Karakiewicz PI. Deuker M, et al. Clin Genitourin Cancer. 2021 Apr;19(2):117-124. doi: 10.1016/j.clgc.2020.11.004. Epub 2020 Dec 2. Clin Genitourin Cancer. 2021. PMID: 33358490
METHODS: Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), we identified patients with upper urinary tract tumors with pure variant histology (UTVH) and pure upper urinary tract urothelial carcinoma (UTUC). Cumulative incidence plots …
METHODS: Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), we identified patients with upper urinary tract …
Tumours of the renal pelvis and ureter. Observations in 170 patients.
Steffens J, Nagel R. Steffens J, et al. Br J Urol. 1988 Apr;61(4):277-83. doi: 10.1111/j.1464-410x.1988.tb13957.x. Br J Urol. 1988. PMID: 3289673 Review.
A study was made of 170 patients with renal pelvis or ureteric tumours, 160 of whom underwent surgery between 1948 and 1981. The most important aetiological factor was chronic phenacetin abuse: 21.7% of 83 patients with renal pelvis tumours and 11.4% o …
A study was made of 170 patients with renal pelvis or ureteric tumours, 160 of whom underwent surgery between 1948 and 1981. T …
Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer?
Park HK. Park HK. Curr Oncol. 2023 Oct 11;30(10):9078-9089. doi: 10.3390/curroncol30100656. Curr Oncol. 2023. PMID: 37887556 Free PMC article.

Patients with squamous cell carcinoma showed a significantly (p < 0.001) lower bone metastasis rate (27.2%) than patients with urothelial carcinoma (UC) (38.3%). ...Significant differences in metastatic behavior were also observed amon

…

Patients with squamous cell carcinoma showed a significantly (p < 0.001) lower bone metastasis rate (27.2%) than patients w

…
High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
Yaegashi H, Izumi K, Kadomoto S, Naito R, Makino T, Iwamoto H, Nohara T, Shigehara K, Kadono Y, Mizokami A. Yaegashi H, et al. Anticancer Res. 2019 Jan;39(1):375-380. doi: 10.21873/anticanres.13122. Anticancer Res. 2019. PMID: 30591483
BACKGROUND: The present study was conducted to investigate whether baseline serum carbohydrate antigen (CA) 19-9 predicts prognosis or treatment effect in patients with advanced urothelial carcinoma (UC). ...RESULTS: Of 40 patients, seven with CA19-9 2 U/ml w …
BACKGROUND: The present study was conducted to investigate whether baseline serum carbohydrate antigen (CA) 19-9 predicts prognosis o …
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
OBJECTIVE: Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scarce, particularly in Japan. We investigated real-world data focusing on patient background, previous treatments, response, survival and adver …
OBJECTIVE: Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scar …
Complications and their management following retroperitoneal lymph node dissection in conjunction with retroperitoneal laparoscopic radical nephroureterectomy.
Kanno T, Kobori G, Ito K, Nakagawa H, Takahashi T, Takaoka N, Somiya S, Nagahama K, Ito M, Megumi Y, Higashi Y, Moroi S, Akao T, Yamada H. Kanno T, et al. Int J Urol. 2022 May;29(5):455-461. doi: 10.1111/iju.14814. Epub 2022 Feb 10. Int J Urol. 2022. PMID: 35144321
OBJECTIVES: To describe the detailed perioperative complications and their management after retroperitoneal lymph node dissection with retroperitoneal laparoscopic radical nephroureterectomy for patients with upper tract urothelial carcinoma at three institutions. M …
OBJECTIVES: To describe the detailed perioperative complications and their management after retroperitoneal lymph node dissection with retro …
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.
Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M, Abdollah F. Seisen T, et al. Eur Urol. 2017 May;71(5):714-718. doi: 10.1016/j.eururo.2016.11.012. Epub 2016 Nov 29. Eur Urol. 2017. PMID: 27912971
Given the growing body of evidence supporting the benefit of primary tumor control for a wide range of metastatic malignancies, we hypothesized that chemotherapy plus radical nephroureterectomy (RNU) is associated with an overall survival (OS) benefit compared to chemother …
Given the growing body of evidence supporting the benefit of primary tumor control for a wide range of metastatic malignancies, we hy …
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies suggest improved outcomes for dual checkpoint inhibition with high ipilimumab doses. ...Adults aged 18 years or older with histologically …
BACKGROUND: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studi …
Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma.
Nazzani S, Mazzone E, Preisser F, Tian Z, Mistretta FA, Shariat SF, Montanari E, Acquati P, Briganti A, Saad F, Carmignani L, Karakiewicz PI. Nazzani S, et al. Eur J Surg Oncol. 2019 Jul;45(7):1238-1245. doi: 10.1016/j.ejso.2018.12.004. Epub 2018 Dec 11. Eur J Surg Oncol. 2019. PMID: 30563773
MATERIALS AND METHODS: Within the SEER database (2004-2014), we identified 2098 patients with histologically confirmed non-metastatic urothelial carcinoma of renal pelvis or ureter who underwent NU with LND. ...LNI rates according to tumo …
MATERIALS AND METHODS: Within the SEER database (2004-2014), we identified 2098 patients with histologically confirmed non-metastatic …
Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Ryoo H, Kim J, Kim T, Kang M, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Sung HH. Ryoo H, et al. Cancer Res Treat. 2021 Jul;53(3):795-802. doi: 10.4143/crt.2020.919. Epub 2020 Dec 28. Cancer Res Treat. 2021. PMID: 33421984 Free PMC article.
PURPOSE: This study aimed to evaluate the effects of bladder cuff method on oncological outcomes in patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. MATERIALS AND METHODS: The records of 1,095 patients treated with RNU pe …
PURPOSE: This study aimed to evaluate the effects of bladder cuff method on oncological outcomes in patients who underwent radical nephroure …
37 results